Ignite Creation Date:
2025-12-25 @ 2:06 AM
Ignite Modification Date:
2026-01-18 @ 4:50 PM
Study NCT ID:
NCT07193160
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-09-25
First Post:
2025-09-18
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy
Sponsor:
Fudan University
Organization: